La vocation d'OncoDiag est de mettre au point et de commercialiser de nouveaux tests non invasifs de suivi, de diagnostic et de dépistage ciblé de cancers.
OncoDiag develops innovative solutions for early diagnosis and monitoring of cancers (bladder, prostate and colorectal cancer). The company is based in Normandy (9 rue de Pacy, 27930 Miserey).
We have clinically validated Urodiag® (CE-IVD), a new personalized noninvasive urine test, affording a diagnostic precision similar to cystoscopy, for the surveillance of bladder cancer. Commercialisation: Q1 2021.
We are developing a prostate cancer aggressivity test: Prostadiag®. From existing tissue biopsies currently performed, this test will allow to limit heavy treatments (radical prostatectomy) only to patients who really need it.
For colorectal cancer, we have pre-validated Colodiag®, a new sensitive noninvasive blood test, affording a diagnostic precision similar to colonoscopy, for screening and early detection of colorectal cancer.
The development of these tests will provide first-rate help for faster and more precise clinical decisions, thereby improving the quality of patient care and reducing health costs.